Novo Nordisk shifts marketing of GLP-1 drugs from obesity 'patients' to lifestyle 'customers'

Novo Nordisk is shifting its GLP-1 marketing strategy, increasingly framing blockbuster drugs like Wegovy as lifestyle "weight loss" products for "customers" rather than medical treatments for "patients." Simultaneously, the company is expanding its pipeline, securing a $2.6 billion licensing deal with Hengrui Pharma for the oral peptide HRS-1596 and advancing CagriSema, which outperformed Eli Lilly's Zepbound in clinical trials. However, medical experts warn that overrelying on high-dose peptides to suppress hunger cues fails to address the root lifestyle causes of metabolic dysfunction.

Novo Nordisk's consumer-focused marketing shift

• ▪Novo Nordisk has utilized consumer-oriented advertising slogans for its GLP-1 drugs globally, including "Live lighter" and "Summer Glow Up."
• ▪Novo Nordisk has shifted its marketing of GLP-1 drugs by referring to people who take its drugs as "customers" rather than "patients."
• ▪Novo Nordisk has removed the labels "weight management" and "anti-obesity" from its Wegovy website, replacing them with the term "weight loss" drug.

Development and trials of CagriSema

• ▪CagriSema, a combination of semaglutide and the long-acting amylin analog cagrilintide, is anticipated to receive a U.S. Food and Drug Administration approval decision in the fourth quarter of 2026.
• ▪A late-stage clinical trial found that a 1 mg dose of Novo Nordisk's CagriSema led to 12.4 percent weight loss in patients with Type 2 diabetes after 60 weeks, compared to 9.1 percent weight loss for patients receiving a 5 mg dose of Eli Lilly's Zepbound.
• ▪In a clinical trial, Novo Nordisk's CagriSema reduced body weight in overweight or obese adults by 21 percent at 68 weeks compared with a placebo.

Licensing agreement for HRS-1596

• ▪On September 29, 2026, Novo Nordisk licensed Hengrui Pharma's phase 1-ready oral GLP-1/GIP dual receptor agonist HRS-1596 globally, excluding mainland China, Hong Kong, Macao, and Taiwan, for up to $2.6 billion, with a $300 million upfront payment and potential royalties.
• ▪Hengrui Pharma has received regulatory approval in China to initiate phase 1 clinical trials of HRS-1596 for weight management and type 2 diabetes.

Dr. Cole's warnings on GLP-1 drugs

• ▪Functional medicine expert Dr. Will Cole warned that "macro-dosing" GLP-1 medications indefinitely is not the solution to metabolic health, arguing that shutting down hunger cues with high peptide doses can act like an "atomic bomb."
• ▪Dr. Will Cole expressed concern that suppressing food cravings with GLP-1 medications could have unintended consequences on other reward-related behaviors, such as social relationships, and may contribute to disordered eating patterns.

Dr. Cole on metabolic health causes

• ▪Dr. Will Cole attributed the epidemic rise of metabolic problems to lifestyle factors, including diets high in ultraprocessed foods, nutrient deficiencies, environmental toxins, stress, and trauma, rather than a pharmaceutical deficiency.
• ▪Dr. Will Cole cited research indicating that an estimated 93 percent of U.S. adults are metabolically unhealthy, leaving only about 7 percent who meet the criteria for optimal metabolic health.

Debatable claims

• ▪Marketing GLP-1 drugs as lifestyle products does more harm than good
• ▪Widespread GLP-1 adoption distracts from addressing the root lifestyle causes of metabolic disease
• ▪Obesity drugs should be treated as lifelong medical therapies rather than temporary lifestyle aids
• ▪Pharmaceutical companies bear the primary responsibility for the over-medicalization of weight loss